Back to Results

A Phase 1a/b Dose-Finding Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Study category: Cancer

Is this Study for You?

Let's Get Started!



Type of Study



University of Colorado Hospital

Principal Investigator
Wells Messersmith,  MD

Wells Messersmith, MD

Study ID

Protocol Number: 19-1458

More information available at NCT04068896

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers